UPDATE: William Blair Downgrades 10X Genomics (TXG) to Market Perform

July 15, 2022 6:25 AM EDT
Get Alerts TXG Hot Sheet
Price: $35.84 -1.65%

Rating Summary:
    7 Buy, 1 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 5 | New: 0
Join SI Premium – FREE
(Updated - July 15, 2022 7:11 AM EDT)

William Blair analyst Brian Weinstein downgraded 10X Genomics (NASDAQ: TXG) from Outperform to Market Perform.

The analyst comments "After the markets closed on Thursday, July 14, 10x provided preliminary top-line results for second quarter 2022. Management expects total revenue for the quarter of roughly $114.5million (-1.2% year-over-year) versus our estimate of $123.2 million (+6.3% year-over-year)and consensus of $127.7 million. By geography, Americas revenue increased 8% year-over-year and 19% sequentially, EMEA revenue decreased 11% year-over-year but increased 25%sequentially, and APAC revenue decreased 15% year-over-year and 47% sequentially. The company plans to update its full year 2022 guidance when it reports full financial results for the second quarter 2022 on August 8. We will update our model following the company’s second-quarter earnings call."

For an analyst ratings summary and ratings history on 10X Genomics click here. For more ratings news on 10X Genomics click here.

Shares of 10X Genomics closed at $43.29 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Downgrades

Related Entities

William Blair, Earnings